PMID- 26663940
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 0027-7622 (Print)
IS  - 2186-3326 (Electronic)
IS  - 0027-7622 (Linking)
VI  - 77
IP  - 4
DP  - 2015 Nov
TI  - Elevated serum interleukin-23 levels in ankylosing spondylitis patients and the 
      relationship with disease activity.
PG  - 621-7
AB  - This study was aimed to evaluate the relationship between serum interleukin-23 
      (IL-23) levels and ankylosing spondylitis (AS).Twenty male patients diagnosed 
      with ankylosing spondylitis according to the 1984 modified New York criteria for 
      AS and twenty male healthy controls were included in this study.The demographic 
      characteristics, clinical and laboratory findings of the patients were recorded. 
      Serum IL-23 levels, C-reactive protein (CRP) and erythrocyte sedimentation rate 
      (ESR) were measured in both the AS and control groups. The Bath ankylosing 
      spondylitis disease activity index (BASDAI), the Bath ankylosing spondylitis 
      functional index (BASFI), and the Bath ankylosing spondylitis metrology index 
      (BASMI) were evaluated as disease activity parameters. The AS patients were 
      divided into two subgroups as active and inactive in respect of CRP, ESR levels 
      and BASDAI scores. The mean serum IL-23 levels of the AS and control groups were 
      334.45+/-176.54 pg/ml and 166.49+/-177.50 pg/ml respectively, and there was a 
      significant difference between the groups. Correlation analysis of serum IL-23 
      levels with clinical and laboratory parameters showed that there were positive 
      correlations between serum IL-23 levels and the BASDAI, BASFI scores in total, 
      active and inactive patients and the BASMI scores in total and inactive patients 
      and negative correlations between serum IL-23 levels and ESR in inactive 
      patients. It was shown that altered serum IL-23 levels were related to AS disease 
      activity. Further studies in large patient series are necessary to investigate 
      the role of IL-23 protein in etiopathogenesis of AS.
FAU - Ugur, Mahir
AU  - Ugur M
AD  - Ataturk University Faculty of Medicine, Department of Physical Medicine and 
      Rehabilitation, Erzurum, Turkey.
FAU - Baygutalp, Nurcan Kilic
AU  - Baygutalp NK
AD  - Ataturk University Faculty of Medicine, Department of Medical Biochemistry, 
      Erzurum, Turkey.
FAU - Melikoglu, Meltem Alkan
AU  - Melikoglu MA
AD  - Ataturk University Faculty of Medicine, Department of Physical Medicine and 
      Rehabilitation, Erzurum, Turkey.
FAU - Baygutalp, Fatih
AU  - Baygutalp F
AD  - Ataturk University Faculty of Medicine, Department of Physical Medicine and 
      Rehabilitation, Erzurum, Turkey.
FAU - Altas, Elif Umay
AU  - Altas EU
AD  - Ataturk University Faculty of Medicine, Department of Physical Medicine and 
      Rehabilitation, Erzurum, Turkey.
FAU - Seferoglu, Buminhan
AU  - Seferoglu B
AD  - Ataturk University Faculty of Medicine, Department of Physical Medicine and 
      Rehabilitation, Erzurum, Turkey.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Nagoya J Med Sci
JT  - Nagoya journal of medical science
JID - 0412011
SB  - IM
PMC - PMC4664593
OTO - NOTNLM
OT  - ankylosing spondylitis
OT  - disease activity
OT  - interleukin-23
EDAT- 2015/12/15 06:00
MHDA- 2015/12/15 06:01
PMCR- 2015/11/01
CRDT- 2015/12/15 06:00
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2015/12/15 06:01 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
PST - ppublish
SO  - Nagoya J Med Sci. 2015 Nov;77(4):621-7.